L

Leap Therapeutics
D

LPTX

0.29510
USD
0.01
(3.54%)
مغلق
حجم التداول
2,345
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
12,228,805
أصول ذات صلة
A
ARCT
0.160
(1.18%)
13.770 USD
BNTX
BNTX
1.570
(1.45%)
109.800 USD
C
CRNX
0.350
(1.19%)
29.800 USD
MRNA
MRNA
0.195
(0.64%)
30.480 USD
T
TBPH
0.060
(0.54%)
11.110 USD
V
VERU
0.02020
(3.45%)
0.60650 USD
المزيد
الأخبار المقالات

العنوان: Leap Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patientswith colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.